MA51582B1 - Conjugués oligomères de sauts d'exons pour la dystrophie musculaire - Google Patents

Conjugués oligomères de sauts d'exons pour la dystrophie musculaire

Info

Publication number
MA51582B1
MA51582B1 MA51582A MA51582A MA51582B1 MA 51582 B1 MA51582 B1 MA 51582B1 MA 51582 A MA51582 A MA 51582A MA 51582 A MA51582 A MA 51582A MA 51582 B1 MA51582 B1 MA 51582B1
Authority
MA
Morocco
Prior art keywords
oligomer conjugates
muscular dystrophy
exon skipping
skipping oligomer
exon
Prior art date
Application number
MA51582A
Other languages
English (en)
Other versions
MA51582A (fr
Inventor
Marco Passini
Gunnar Hanson
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority claimed from PCT/US2017/066509 external-priority patent/WO2018118662A1/fr
Publication of MA51582A publication Critical patent/MA51582A/fr
Publication of MA51582B1 publication Critical patent/MA51582B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des conjugués oligomère antisens capables de se lier à un site cible sélectionné du gène de la dystrophine humaine pour induire le saut de l'exon 53 sont décrites.
MA51582A 2016-12-19 2017-12-14 Conjugués oligomères de sauts d'exons pour la dystrophie musculaire MA51582B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436223P 2016-12-19 2016-12-19
PCT/US2017/066509 WO2018118662A1 (fr) 2016-12-19 2017-12-14 Conjugués oligomères de sauts d'exons pour la dystrophie musculaire

Publications (2)

Publication Number Publication Date
MA51582A MA51582A (fr) 2019-10-23
MA51582B1 true MA51582B1 (fr) 2022-10-31

Family

ID=65895705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51582A MA51582B1 (fr) 2016-12-19 2017-12-14 Conjugués oligomères de sauts d'exons pour la dystrophie musculaire

Country Status (2)

Country Link
AR (1) AR110390A1 (fr)
MA (1) MA51582B1 (fr)

Also Published As

Publication number Publication date
MA51582A (fr) 2019-10-23
AR110390A1 (es) 2019-03-27

Similar Documents

Publication Publication Date Title
SA519402143B1 (ar) مترافقات أوليجومرات تخطي الإكسون للحَثَل العَضَلِيّ
MX2019006882A (es) Conjugados de oligomeros de omision de exon para distrofia muscular.
MX2019006879A (es) Conjugados de oligomeros de omision de exon para distrofia muscular.
CY1121876T1 (el) Συνθεσεις παρακαμψης εξωνιου για τη θεραπεια της μυϊκης δυστροφiας
MA45618A (fr) Sauts d'exons oligomères pour la dystrophie musculaire
EA201991450A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MX2019008209A (es) Composiciones para el salto del exon para el tratamiento de distrofia muscular.
CY1123119T1 (el) Αντινοηματικο νουκλεϊκο οξυ
EA201591792A1 (ru) Улучшенные композиции для лечения мышечной дистрофии
EA202092772A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA51582B1 (fr) Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
MA51587B1 (fr) Conjugués oligomère de sauts d'exons pour la dystrophie musculaire
EA202191601A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MA47015B1 (fr) Conjugués oligomères de sauts d'exons pour la dystrophie musculaire
MA47495A (fr) Compositions anti-inflammatoires comprenant des inhibiteurs d'irak et de jak
FR3033489B3 (fr) Guide pour le positionnement d'attaches orthodontiques
GB201911464D0 (en) Genetic modification site
EA201991458A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EA201991449A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EA201990115A1 (ru) Олигомеры для пропуска экзона при мышечной дистрофии
EP4219717A3 (fr) Oligomères à saut d'exon pour la dystrophie musculaire